Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
February 28, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received at the Company’s investigator meeting and by Iomab-B’s scientific advisory board - Product theater...
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
February 08, 2018 08:00 ET
|
Actinium Pharmaceuticals
- Mr. Kapur joins Actinium with more than two decades of biopharmaceutical commercial experience at Johnson & Johnson, BAXALTA and Bristol-Myers Squibb - Global leader with deep expertise in...
Actinium Pharmaceuticals Announces Rights Offering
February 01, 2018 16:05 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it has filed a preliminary prospectus supplement as...
Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs
January 08, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Dr. Ludwig brings over 20 years of leadership and management expertise from Eli Lilly and Company and Imclone Systems, Inc. in oncology antibody therapeutics discovery and development where he...
Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual Meeting
December 12, 2017 07:30 ET
|
Actinium Pharmaceuticals
Higher cell death observed with Actinium-225 labeled daratumumab with up to ten-fold higher potency as compared to naked daratumuambARC of Daratumumab-Actinium-225 labeled with high yield, high...
Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M
December 11, 2017 16:15 ET
|
Actinium Pharmaceuticals
Analysis of patient data from a large U.S. library revealed that twenty-five percent of Multiple Myeloma patients have CD33 expression on their multiple myeloma cells supporting the rational for...
TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
December 11, 2017 08:00 ET
|
TeneoBio, Inc
MENLO PARK, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- TeneoBio, Inc. yesterday presented preclinical data on its lead therapeutic candidate, TNB-383B, a multivalent anti-BCMAxCD3 at the American...
Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
December 05, 2017 07:30 ET
|
Actinium Pharmaceuticals
Phase 2 clinical trial planned for 2018, Actimab-MDS intended to be a bridge to a bone marrow transplant, the only curative treatment option for patients with myelodysplastic syndromeTrial principal...
Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform
November 29, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Poster presentation to detail results from ongoing Phase 2 trial for Actimab-A, Actinium’s CD33 targeting ARC or Antibody Radio-Conjugate, designed to explore Actimab-A’s efficacy in patients newly...
Actinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology Platform
November 14, 2017 08:00 ET
|
Actinium Pharmaceuticals
- AWE Program launched post successful demonstration of Actinium’s “Biobetter” capabilities as evidenced by superior experimental results with actinium-225 labeled daratumumab when compared to...